NCT03247140View on ClinicalTrials.gov

The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Male Volunteers Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 10, 2017

Primary Completion Date

August 7, 2017

Study Completion Date

November 27, 2017

Conditions
Hypertension With Dyslipidemia
Interventions
DRUG

JLP-1401

Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)

DRUG

Telmisartan/Amlodipine, Rosuvastatin

Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)

Trial Locations (1)

Unknown

Chonbuk National University Hospital, Jeonju

Sponsors
All Listed Sponsors
lead

Jeil Pharmaceutical Co., Ltd.

INDUSTRY